Empagliflozin Reduced Liver Fat in Type 2 Patients with Nonalcoholic Fatty Liver Disease

@inproceedings{Sederstrom2018EmpagliflozinRL,
  title={Empagliflozin Reduced Liver Fat in Type 2 Patients with Nonalcoholic Fatty Liver Disease},
  author={Jill Sederstrom},
  year={2018}
}
Diabetes drug empagliflozin reduces fat levels in type 2 patients, which may reduce risk of severe liver disease. 

Topics from this paper.

Similar Papers